Sequence-based protein kinase inhibition: applications for drug development.
Wexler
Isaiah D
ID
Hadassah-Mount Scopus University Hospital, Jerusalem, Israel.
Niv
Masha Y
MY
Reuveni
Hadas
H
D000818:Animals; D017209:Apoptosis; D001665:Binding Sites; D014408:Biomarkers, Tumor; D001709:Biotechnology / Q000379:methods*; D045744:Cell Line, Tumor; D002470:Cell Survival; D002626:Chemistry, Pharmaceutical / Q000379:methods; D017868:Cyclic AMP-Dependent Protein Kinases / Q000737:chemistry; D015195:Drug Design; D004345:Drug Industry / Q000379:methods / Q000639:trends; D006801:Humans; D008024:Ligands; D051379:Mice; D008958:Models, Molecular; D009368:Neoplasm Transplantation; D009842:Oligopeptides / Q000494:pharmacology; D010455:Peptides / Q000737:chemistry; D011487:Protein Conformation; D047428:Protein Kinase Inhibitors / Q000737:chemistry* / Q000494:pharmacology*
D014408:Biomarkers, Tumor; D008024:Ligands; D009842:Oligopeptides; D010455:Peptides; D047428:Protein Kinase Inhibitors; C483318:myristyl-glycyl-leucyl-valyl-threonyl-diiodotyrosyl-lysyl-lysyl-isoleucyl-N(epsilon)-benzoyllysinamide; D017868:Cyclic AMP-Dependent Protein Kinases